Article Details
Retrieved on: 2022-10-30 15:52:37
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The firm presently has an “overweight” rating on the biotechnology company's stock. Morgan Stanley's target price would indicate a potential upside of ...
Article found on: reporter.am
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here